Instead, combining MEK+BCL-XL inhibition plus ICI treatment enriches the tumor microenvironment with neutrophil, monocyte, and macrophage clusters (Figures 6C–6D, S6A and S6B). The gene discussed is MAP2K7; the disease is neoplasm.